Diabetes can frequently result in peripheral diabetic neuropathy (PDN), a lifethreatening illness that impairs the motor and sensory abilities of peripheral nerves. Prompt identification and management of peripheral neuropathy are essential to avert permanent nerve impairment and enhance the well-being of affected individuals. In addition, axonal degeneration is usually detected at a late stage of the disease and serves as a basis for developing modern diagnostic techniques. Novel biomarkers that can detect PDN early and track its development are thus required. In this review, we highlight the most recent developments in identifying and verifying putative biomarkers for PDN, emphasizing their connections to the pathophysiology and clinical presentations of the illness. The challenges and opportunities for developing biomarker-based diagnostic and therapeutic strategies for PDN are also discussed. It is suggested that biomarkers help predict the response and outcome of PDN treatments, such as poly (ADP-ribose) polymerase inhibitors and regenerative medicine.

The immune system is essential for tissue regeneration and repair. Indeed, the rate and outcome of the healing process, including the degree of scarring and the restoration of organ function, are greatly influenced by the immune response to tissue damage. Therefore, since therapies based on stem cells and growth factors have not yet shown widespread clinical success, using biomaterials and drug delivery systems to modulate immune components is becoming an appealing approach in regenerative medicine. A deeper comprehension of the immune system's role in tissue repair and regeneration is required to develop effective reparatory and regenerative therapies. This understanding should be accompanied by numerical data or quantitative information that links the narrative flow with specific analyses and findings. We start by summarizing the functions of the different immune cell types in tissue repair. The basic concept, applications, and constraints of regulatory T (Treg) cell-based therapy, a subset of cellbased immunotherapy, are then covered. Finally, we address immunotherapy strategies based on biomaterials, which use different biomaterials to modulate immune cells to promote tissue repair and regeneration. Conventional breast cancer treatment includes surgery, chemotherapy, radiation therapy, and targeted medications, including PARP inhibitors and HER2 monoclonal antibodies. Cancer stem cells (CSCs) and triple-negative breast cancer (TNBC) are linked to treatment resistance and recurrence. To overcome the complexity of breast cancer and improve clinical outcomes, this study highlights the critical intersection of regenerative medicine, nanotechnology, and personalized therapies.

In medicine, bioavailability is the percentage of a drug that enters the bloodstream and can be used to treat a patient. It has proven challenging throughout time to develop techniques that allow oral administration of most drugs, regardless of their properties, to achieve therapeutic systemic availability. This will be an impressive feat, considering that over 90% of pharmaceuticals are known to have limitations on their oral bioavailability. Improving bioavailability is crucial for optimizing the efficacy and safety of drugs. This review covers a wide range of techniques, including physical, chemical, and formulation approaches, highlighting their mechanisms, advantages, and limitations. Inhibitions of efflux pumps, inhibition of presystemic metabolism, and innovative drug delivery systems that capitalize on the gastrointestinal regionality of medicines are some of the new techniques that have drawn increased interest. Nanotechnology in pharmaceuticals is also being used in this field. We have collected the literature data from 2009 to 2024 using Science Direct, PubMed/Medline, Scopus, and Google Scholar.

Objective: This work aims to evaluate the combined anti-diabetic effects of metformin and catechin in vitro and in silico. Methods: In vitro, anti-diabetic potentials of (α-amylase and α-glucosidase) catechin, metformin, and a combination of catechin and metformin were studied at different concentrations using acarbose as standard. An in silico study determined their binding interactions with α-amylase (PDB ID: 1hvx) and α-glucosidase (PDB ID: 5zcb). The molecular docking study further revealed the binding energy and interacting residues of the docked 3D structure of the catechin, metformin, and acarbose as a standard with the α-amylase and α-glucosidase receptors. Results: The result showed that a 100 μg/ml dosage of metformin and catechin demonstrated higher enzyme inhibition compared to the separate treatments. Compared to metformin and acarbose, the results of this study showed that catechin with 1hvx and 5zcb exhibited the highest binding affinity interaction via hydrogen bonding and pi-interaction. Conclusion: The study's findings showed that when compared to metformin and acarbose, catechin with 1hvx and 5zcb showed the highest binding affinity relationship via hydrogen bonding and pi-interaction. Higher levels of enzyme inhibition were seen when metformin and catechin were administered together than when either medication was taken alone. Based on the aforementioned report, we deduced that metformin and catechin together had more potent antidiabetic actions in vitro. We can conclude that catechin, in combination with metformin, may be developed into a possible oral hypoglycemic drug. High-affinity capacity catechin was found to have a strong inhibitory effect on α-glucosidase and α-amylase. The possible interaction pathways between these main inhibitors and two digestive enzymes were identified by docking studies. This study demonstrates the efficaciousness of catechin in preventing and treating posthyperglycemia. This work suggests interesting directions for future research and clinical applications by endorsing the use of these phytocompounds as powerful anti-diabetic pharmaceuticals, either as single compounds or in combination with synthetic drugs.

In spite of the fact that many medicinal plants have been truly utilized for the management of diabetes all through the world, very few of them have been reported scientifically. Recently, a diverse variety of animal models have been established to better understand the pathophysiology of diabetes mellitus, and new medications to treat the condition have been introduced in the market. Flavonoids are naturally occurring substances that can be found in plants and various foods and may have health benefits in the treatment of neuropathic pain. Flavonoids have also been shown to have an anti-inflammatory impact that is significant to neuropathic pain, as indicated by a decrease in several pro-inflammatory mediators such TNF-, NF-B IL-6, and IL-1. Flavonoids appear to be a viable novel therapy option for macrovasular complications in preclinical models; however, human clinical data is still inadequate. Recently, several in silico, in-vitro and in-vivo aproaches were made to evaluate mechanisms associated with the pathogenesis of diabetes in a better way. Screening of natural antidiabetic agents from plant sources can be analysed by utilizing advanced in-vitro techniques and animal models. Natural compounds, mostly derived from plants, have been studied in diabetes models generated by chemical agents in the majority of research. The aim of this work was to review the available in silico, in-vitro and animal models of diabetes for screening of natural antidiabetic agents. This review contributes to the scientist's design of new methodologies for the development of novel therapeutic agents having potential antihyperglycemic activity.

Background and Aims: Diabetes mellitus is a chronic metabolic disorder affecting global public health. Since ancient, natural-based compounds are widely used for multiple indications of diabetes. Methods: The natural-based (-)-Epicatechin has enormous biological functions including antioxidant and anti-inflammatory activities. This review mainly focuses on the importance of epicatechin in the control of pathogenesis involved in diabetic mellitus. Additionally, its possible mechanisms involved in beta cell regeneration, insulin secretion, and insulin sensitivity. Results: The present article explored the potential antioxidant, mitochondrial protection, and antiinflammatory properties using the preclinical and clinical model, and also established the role of (-)- Epicatechin in the mitigation of diabetic-associated complications. Lastly, the article mentioned the limitation of the use of epicatechin. Conclusion: This will provide new insight to budding scientists for the development of novel bioactivebased pharmaceuticals for the management of diabetic mellitus.

Objective: This study aimed to assess the combinational antidiabetic effect of catechin and metformin in streptozotocin (STZ)-induced diabetic rats. Methods: Wistar rats were chosen and divided into five groups (n=6). STZ at the dose of 55 mg/kg was used intraperitoneally for the induction of diabetes. The combination of catechin (CTN) and metformin (MET) was administered to diabetic rats. The changes in fasting blood sugar, body weight, Hb, HbA1c, creatinine, lipid profiles (TC, HDL, LDL, and TG), biochemical parameters (SGOT, SGPT, and ALP), and endogenous antioxidant parameters (SOD, GSH, and catalase) were assessed. Histopathological study of the β-cells in islets of the pancreas, kidney tubules, and liver cells was conducted in all groups. Results: The result showed a significant reduction (p < 0.001) in blood sugar in the CTN and METtreated group compared to the control group. The combination of CTN (50 mg/kg) and MET (22.5 mg/kg) significantly restored the creatinine levels and urine volumes, SGOT, SGPT, and ALP, compared to a single administration dose. The abnormal lipid profile levels (TC, LDL, TG, and HDL) and antioxidant enzymes (SOD, GSH, catalase) in diabetic control rats were restored to average levels in a significant manner. Histopathological results revealed significant alterations, including hypertrophy of islets and mild degeneration, renal necrosis, and inflammation of hepatocytes. Conclusion: The findings indicate that a combination of therapy (CTN+MET) improved the protective effect of the pancreas, kidney, and liver, suggesting that the combination shows a potential antidiabetic effect.

Comparison effect of Pioglitazone and Glimepiride alone on renal function marker in experimentally induced renal damage in diabetic rats.Jagdish Kakadiya, Nehal Shah

Pharmacological interaction between anti diabetic agents with herb poses a challenge for safety and efficacy for the management of diabetes. The population belief that the herbs are safe to human health as they are obtained from natural sources and contain many active constituents. Due to the great sources of medicinal agent in herbs, the various parts of herbs have been used in the treatment of diabetes mellitus. Sometime the antidiabetic active constituents of medicinal herbs and their secondary metabolites interacted with the synthetic standard drugs when combined together, action may be synergetic or antagonistic. Therefore in this review article we are emphasizing the mechanism of interaction between standard synthetic anti diabetic drug with medicinal herbs in relation to its pharmacokinetic and pharmacodynamics effect, the evidence of beneficial interaction were identified for future therapy to treat diabetes.

: Introduction: Traditional medicines for mammary tumour are unreasonable and have genuine symptoms. Non-ordinary normal medications have increased wide acknowledgment because of their assurance of a cure with negligible or no symptoms, however minimal experimental confirmation exists. One such basic cure is the leaves of the Euphorbia hirta plant. Methods: It is initially reported utilization of the fluid concentrate of Euphorbia hirta leaves breast cancer cells. The capacity of the concentrate to impel apoptosis and corruption in the human bosom malignancy cell line MCF-7, contrasted with typical human skin fibroblasts (MDA MB-231), was dictated by morphological changes in the cells utilizing light microscopy, DNA fragmentation, and brilliant stains (Annexin V and Propidium Iodide) utilizing Flow Cytometry and fluorescent microscopy. Results: Apoptosis was instigated in both cells, and more in MCF-7, when they were treated with 25% and half concentrate, while rot was watched mostly after presentation to raised concentrate fixations (75%). DNA discontinuity came about for both cells, in a period and dosage subordinate way. Both cells, at all concentrate fixations, demonstrated no critical contrasts in the quantity of living, dead, apoptotic, and necrotic cells. Conclusion: At long last, the outcomes might show that apoptotic changes in MCF-7 might be free of caspase-3, which is included in apoptosis and is inadequate in MCF-7 cells.Key words: Apoptosis, Aqueous extract, Euphorbia hirta leaves, Human breast cancer cells, Necrosis.This article has been retracted from Journal of Young Pharmacists on 16th December 2019. Retraction notice will be published in Jan-Mar, 2020 issue.